3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Pancreatic Neoplasms
3
Ovarian Neoplasms
2
Insulin-Like Growth Factor I, Resistance To
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Small Cell Lung Carcinoma
1
Sarcoma
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Pleural Effusion, Malignant
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Gastrointestinal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
talimogene laherparepvec
1
rilotumumab
1
ganitumab
1
camrelizumab
1
Thiostrepton
1
Silver Nitrate
1
Nivolumab
1
Etoposide
1
Cisplatin
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Pleural Effusion, Malignant
×
ganitumab
×
Clear all
NCT00791154
2024-08-23
SCLC
NantCell, Inc.
Phase 1/2
Terminated
213 enrolled
16 charts